In part 2 of his interview with small-cap equity research firm, OutsideIn Research, Access Pharmaceuticals’ CEO Jeffrey B. Davis provided an in-depth look at the Company’s product pipeline.
COBALAMIN ORAL DRUG DELIVERY / TARGETED DRUG DELIVERY TECHNOLOGY
Q: Can you help explain to the readers your Cobalamin platform technology, in simple layman’s terms?
Jeffrey B. Davis: Sure, I can certainly try. It’s easiest to explain in the context of the Oral Drug Delivery activity ongoing, so I’ll use that first to explain how the technology works.
First, you should know that drugs have to be injected today because the molecule itself is too large, or simply physically too big to get across the digestive tract. Because they can’t get across your digestive tract, some drugs need to be injected directly into your blood stream. Clearly, a technology that could transform “injectable” drugs into “oral” or pill forms of drugs would be very helpful to the pharmaceutical industry, and very valuable.
Read more »
Access’ President and CEO, Jeffrey B. Davis recently conducted a Q&A with OutsideIn Research, a small-cap equity research firm. The interview was published in two parts, the first of which is below:
Q: Tell us about Access Pharmaceuticals, its history and its focus.
Jeffrey B. Davis: Access Pharma is a Dallas-based biotechnology company that’s been around for many years, but underwent a re-engineering and re-focusing roughly three years ago. At that time, the Company refocused on its oncology assets, and divested of its dermatology and wound healing assets. The three year “re-engineering” effort has been a great success, resulting in its first FDA-approved therapy, MuGard, significant development in its two Phase 2 assets, ProLindac and Thiarabine, and great progress in its Cobalamin Oral Drug Delivery and Targeted Drug Delivery platforms. Over that period, the Board of Directors was revamped, new management expertise brought in, a new strategy put in place, and many partnerships being signed. I believe that it positions Access Pharmaceuticals very well for success, and I think it’s a great time for the investment community to take a fresh look at our Company.
Read more »
DALLAS, TX and NEW YORK, NY, August 24, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Director of Chemistry and Quality, Dr. Ric Zarzycki will give an invited presentation today on the Company’s Cobalamin nanoparticle technology at a thought-leadership symposium being held at the American Chemical Society’s (“ACS”) 240th National Meeting & Exposition, at Boston Convention and Exhibition Center in Boston, Massachusetts, August 22-26, 2010. The conference symposium titled, “Multifunctional Nanoparticles for Drug Delivery and Imaging”, will focus on the advancement of nanotechnology in the pharmaceutical and diagnostic industries. Dr. Zarzycki will highlight the distinct characteristics of Access’ Cobalamin nanotechnology and the potential key role it will play in the future treatment of various diseases.
Read more »
Phase I/II Clinical Trial to be conducted at UT MD Anderson Cancer Center
DALLAS, TX and NEW YORK, NY August 3, 2010
Access Pharmaceuticals, Inc. (OTCBB: ACCP), today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analogue for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.
Read more »
Digg!
Del.icio.us
MuGard's ready-to-use viscous liquid is tasteless, and is safe to swallow. See